<DOC>
	<DOCNO>NCT01687478</DOCNO>
	<brief_summary>The purpose study assess efficacy safety olanzapine fluoxetine compare placebo fluoxetine treatment treatment-resistant depression ( TRD ) Chinese participant .</brief_summary>
	<brief_title>A Study Olanzapine Fluoxetine Treatment-resistant Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Have single recurrent unipolar major depressive disorder ( MDD ) without psychotic feature Diagnostic Statistical Manual Mental Disorders , Fourth EditionText Revision ( DSMIVTR ) clinical assessment Have total score ≥22 17item Hamilton Depression Rating Scale ( HAMD17 ) screen randomization Have treatmentresistant depression ( TRD ) , define failed achieve satisfactory antidepressant response , opinion investigator , separate treatment course least 2 different antidepressant , fluoxetine , adequate dosage duration ( ≥6 week ) within current major depressive episode Have diagnosis Parkinson 's disease relate disorder Have current lifetime diagnosis follow condition , accord DSMIVTR criterion : Schizophrenia ; Schizophreniform Disorder ; Schizoaffective Disorder ; Delusional Disorder ; Psychotic Disorder Not Otherwise Specified ; Bipolar Disorder I II ; Delirium type ; Dementia type ; Amnestic Disorder ; SubstanceInduced Disorder ; Psychotic Disorder due General Medical Condition Have current diagnosis postpartum depression MDD seasonal pattern define DSMIVTR Have paranoid , schizoid , schizotypal , antisocial , borderline personality disorder ( Axis II ) comorbid primary diagnosis , base DSMIVTR criterion Have DSMIVTR substance dependence/abuse willing avoid use substance ( include dependence nicotine caffeine ) within 30 day screen Are actively suicidal judgment investigator Have uncorrected narrowangle glaucoma Have one seizure without clear resolve etiology Have leukopenia Have acute , serious , unstable medical condition Have increase serum prolactin concentration screen Have ratecorrected cardiac QT interval , calculate use Bazett 's formula ( QTc Bazett 's [ QTcB ] ) , Electrocardiogram ( ECG ) &gt; 450 millisecond ( male ) &gt; 470 millisecond ( female ) screen Have history allergic reaction olanzapine , fluoxetine , olanzapine combination fluoxetine Have treatment olanzapine , fluoxetine , olanzapine combination fluoxetine withdrawn due clinically significant and/or intolerable adverse effect within 6 month screen Have receive treatment remoxipride within 6 month randomization Have receive treatment depot antipsychotic within one dose interval randomization Have receive electroconvulsive therapy ( ECT ) vagus nerve stimulation ( VNS ) treatment within current MDD episode , history failure respond adequate treatment course ECT VNS , expect require ECT VNS time study Have receive previous treatment clozapine Have receive treatment monoamine oxidase inhibitor ( MAOI ) within 14 day screen , expect need MAOI treatment time study 5 week study discontinuation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>